<DOC>
	<DOCNO>NCT02421185</DOCNO>
	<brief_summary>The purpose study determine recommend Phase 2 dose [ RP2D ] ) objective response rate JNJ-42756493 ( erdafitinib ) advance hepatocellular carcinoma ( HCC ) participant fibroblast growth factor ( FGF ) 19 amplification .</brief_summary>
	<brief_title>Study Evaluate Safety , Pharmacokinetics , Pharmacodynamics JNJ-42756493 ( Erdafitinib ) Participants With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multicenter ( one hospital medical school team work medical research study ) , 2 part ( First , dose escalation Phase second , dose expansion Phase ) study evaluate safety , pharmacokinetics , pharmacodynamics , clinical response JNJ-42756493 ( erdafitinib ) Asian participant advance HCC . The duration study approximately 11 month per participant . The study consist 2 period : Screening ( 28 day study commences Day 1 ) ; Open-label Treatment ( dose escalation portion trial [ Part 1 ] ) , participant enrol cohort increase dose level JNJ-42756493 ( erdafitinib ) 28 day treatment cycle . Part 2 , cohort expansion part trial , explore recommend phase 2 dose ( RP2D ) JNJ-42756493 ( erdafitinib ) determine Part 1 ; follow-up Phase ( 6 month ) . Blood sample collect evaluation safety , pharmacokinetics , pharmacodynamics , predictive biomarkers pre-dose post-dose study treatment . Recommended Phase 2 dose ( RP2D ) JNJ-42756493 ( erdafitinib ) evaluate primarily . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Histologically cytologically confirm hepatocellular carcinoma ( HCC ) . ( histology cytology prior tumor biopsy specimen acceptable ) . For Part 1 continuous dose regimen Part 2 , HCC participant must fibroblast growth factor ( FGF ) 19 amplification base central laboratory result Participant must advance disease meet follow criterion : Disease progression previous surgical localregional therapy , ; Disease ineligible surgical localregional therapy systemic therapy ; Received 1 line systemic therapy ( Participants intolerant previous systemic therapy allow . ) Cirrhotic status ChildPugh class A : Participants ChildPugh class B score 7 may consider Part 2 pharmacokinetic ( PK ) safety issue identify Part 1 subject ChildPugh class A Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Participants adequate bone marrow , liver , renal function , electrolytes accord protocoldefined criterion within 14 day first dose study drug Negative pregnancy test ( urine serum beta human chorionic gonadotropin [ beta ( b ) hCG ] ) Screening woman child bear potential sexually active Received systemic chemotherapy , targeted therapy , definitive radiotherapy , treatment investigational anticancer agent within 2 week ( case nitrosoureas mitomycin C , within 6 week ; case immunotherapy , within 4 week ) first administration study drug Prior liver transplant Known fibrolamellar HCC mixed cholangiocarcinoma HCC Clinically active serious infection great ( &gt; ) Common Terminology Criteria adverse event ( AEs ) grade 2 Participants persistent calcium phosphate &gt; upper limit normal ( ULN ) screening ( within 14 day prior Day 1 Cycle 1 predose Cycle 1 ) despite medical management calcium phosphate level</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>JNJ 42756493</keyword>
	<keyword>pan-Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor</keyword>
</DOC>